NCT02172885
Source recordAI-normalized
Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta
The purpose of this study is to determine the safety and effectiveness of five infusions of characterized HLA-identical MSC in non immunosuppressed children with Osteogenesis Imperfecta (OI).
AI analysis
Indication: Osteogenesis Imperfecta
Modality: cell therapy
Target: Mesenchymal Stem Cells
Sponsor: Hospital de Cruces
Source URL: ClinicalTrials.gov
Source updated: Oct 03, 2023
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Mesenchymal Stem Cells
View original source fields
Condition raw: Osteogenesis Imperfecta
Condition normalized: Osteogenesis Imperfecta
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: Mesenchymal Stem Cells
Target normalized: Mesenchymal Stem Cells